Hypofractionated radiotherapy as salvage for rising prostate-specific antigen after radical prostatectomy

被引:19
|
作者
Lee, LW
McBain, CA
Swindell, R
Wylie, JP
Cowan, RA
Logue, JP [1 ]
机构
[1] Christie Hosp, Dept Clin Oncol, Manchester M20 4BX, Lancs, England
[2] Christie Hosp, Dept Med Stat, Manchester, Lancs, England
关键词
prostate cancer; radical prostatectomy; radiotherapy; salvage;
D O I
10.1016/j.clon.2004.07.006
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aims: To review the outcome of men receiving hypofractionated salvage radiotherapy for rising prostate-specific antigen (PSA) after radical prostatectomy. Materials and methods: A. retrospective analysis of 61 men referred for salvage radiotherapy for biochemical relapse after radical prostatectorny was conducted. Twenty-four men receiving hormonal therapy or with follow-up of less than 12 months were excluded. Thirty-seven men were identified, median age 64 years, median preoperative PSA 11 ng/ml (5.6-60 ng/ml), Gleason scores < 7: 70%, Gleason scores greater than or equal to 7: 30%. Twenty-seven men had positive surgical resection margins, eight had seminal-vesicle involvement and one had lymph-node involvement. Diagnosis of failure after radical prostatectomy was made on rising PSA in all cases; 19 men also had positive magnetic resonance imaging, 11 abnormal digital rectal examination and nine positive biopsy. Radiotherapy was delivered conformally to the prostatic fossa, 50-52.5 Gy in 20 fractions over 4 weeks. Date of failure after radiotherapy was defined by the American Society for Therapeutic Radiology and Oncology (ASTRO) consensus criteria or as date of commencement of hormonal therapy for rising PSA. Results: Median time front radical prostatectorny to radiotherapy was 30.6 months (8-68 months); median pre-radiotherapy PSA was 2.9 ng/ml (0.5-11.4 ng/ml). PSA response after radiotherapy was seen in 33 out of 37 (89%) patients. At median follow-up of 36 months (20-85 months), 28 out of 37 remained disease-free. Thirteen more patients have had two consecutive PSA rises. Actuarial 3-year disease-free survival is 74%. No patient has developed metastases or died of prostate cancer. Pre-radiotherapy PSA less than 2 ng/ml predicted disease-free survival (P = 0.027). No acute toxicity greater than Radiation Therapy Oncology Group (RTOG) G2 was observed. Conclusions: Salvage radiotherapy after radical prostatectomy achieved durable biochemical control in most patients. Outcome is improved if radiotherapy is delivered when PSA is less than 2 ng/ml. A policy of close monitoring after radical prostatectomy with early referral for salvage radiotherapy is advocated. (C) 2004 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:517 / 522
页数:6
相关论文
共 50 条
  • [31] The impact of prostate-specific antigen persistence after radical prostatectomy on the efficacy of salvage radiotherapy in patients with primary N0 prostate cancer
    Bartkowiak, Detlef
    Siegmann, Alessandra
    Boehmer, Dirk
    Budach, Volker
    Wiegel, Thomas
    BJU INTERNATIONAL, 2019, 124 (05) : 785 - 791
  • [32] Salvage Radiation Therapy for Increasing Prostate-Specific Antigen After Radical Prostatectomy: Who, When, and How?
    Fossati, Nicola
    Cozzarini, Cesare
    Fiorino, Claudio
    Gandaglia, Giorgio
    Montorsi, Francesco
    Briganti, Alberto
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04) : 469 - +
  • [33] Defining the Most Informative Intermediate Clinical Endpoints for Patients Treated with Salvage Radiotherapy for Prostate-specific Antigen Rise After Radical Prostatectomy
    Martini, Alberto
    Fossati, Nicola
    Karnes, R. Jeffrey
    Boorjian, Stephen A.
    Boeri, Luca
    Bossi, Alberto
    Di Muzio, Nadia
    Cozzarini, Cesare
    Chiorda, Barbara Noris
    Gandaglia, Giorgio
    Robesti, Daniele
    Bartkowiak, Detlef
    Boehmer, Dirk
    Shariat, Shahrokh F.
    Goldner, Gregor
    Battaglia, Antonino
    Joniau, Steven
    Berghen, Charlien
    De Meerleer, Gert
    Fonteyne, Valerie
    Ost, Piet
    Van Poppel, Hein
    Montorsi, Francesco
    Wiegel, Thomas
    Briganti, Alberto
    EUROPEAN UROLOGY ONCOLOGY, 2021, 4 (02): : 301 - 304
  • [34] Impact of pathological tumor stage for salvage radiotherapy after radical prostatectomy in patients with prostate-specific antigen &lt; 1.0 ng/ml
    Umezawa, Rei
    Ariga, Hisanori
    Ogawa, Yoshihiro
    Jingu, Keiichi
    Matsushita, Haruo
    Takeda, Ken
    Fujimoto, Keisuke
    Sakayauchi, Toru
    Sugawara, Toshiyuki
    Kubozono, Masaki
    Narazaki, Kakutaro
    Shimizu, Eiji
    Takai, Yoshihiro
    Yamada, Shogo
    RADIATION ONCOLOGY, 2011, 6
  • [35] Prospective assessment of gastrointestinal and genitourinary toxicity of salvage radiotherapy for patients with prostate-specific antigen relapse or local recurrence after radical prostatectomy
    Pearse, Maria
    Choo, Richard
    Danjoux, Cyril
    Gardner, Sandra
    Morton, Gerard
    Szumacher, Ewa
    Lorlaw, Andrew
    Cheung, Patrick
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (03): : 792 - 798
  • [36] Predictors of prostate bed recurrence on magnetic resonance imaging in patients with rising prostate-specific antigen after radical prostatectomy
    Nasser, Nicola J.
    Chernyak, Victoria
    Shankar, Viswanathan
    Garg, Madhur
    Bodner, William
    Kalnicki, Shalom
    Klein, Jonathan
    CUAJ-CANADIAN UROLOGICAL ASSOCIATION JOURNAL, 2021, 15 (01): : E22 - E28
  • [37] Prostate-specific antigen is a predictor of the efficacy of salvage radiation therapy in patients with recurrent prostate cancer after radical prostatectomy
    Bulychkin, P., V
    Tkachev, S., I
    Matveev, V. B.
    Nazarenko, A., V
    ONKOUROLOGIYA, 2019, 15 (02): : 66 - 72
  • [38] Prostate-Specific Membrane Antigen PET/Magnetic Resonance Imaging for the Planning of Salvage Radiotherapy in Patients with Prostate Cancer with Biochemical Recurrence After Radical Prostatectomy
    Elschot, Mattijs
    Selnaes, Kirsten Margrete
    Langorgen, Sverre
    Johansen, Hakon
    Bertilsson, Helena
    Tandstad, Torgrim
    Bathen, Tone Frost
    PET CLINICS, 2019, 14 (04) : 487 - +
  • [39] Management of patients with an increasing prostate-specific antigen after radical prostatectomy
    Khan M.A.
    Partin A.W.
    Current Urology Reports, 2004, 5 (3) : 179 - 187
  • [40] Predictors of Persistent Prostate-Specific Antigen Persistence after Radical Prostatectomy
    Guo, Chenhao
    Zuo, Kangwei
    Zhao, Qi
    Zhang, Yongjuan
    Jiang, Nan
    Jing, Suoshi
    Yang, Qiaokai
    Li, Xiumei
    Shang, Panfeng
    Li, Weiping
    JOURNAL OF LAPAROENDOSCOPIC & ADVANCED SURGICAL TECHNIQUES, 2024,